 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...5758596061626364656667...132133» |
- Inlyta (axitinib) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
[VIRTUAL] A phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_659;
P2/3
Although the study failed to demonstrate a significant PFS benefit per investigator assessment, axitinib in combination with octreotide LAR demonstrated activity and had a tolerable safety profile in patients with advanced G1-2 extra-pancreatic NETs. Data base cleaning and central blinded radiological PFS assessment are currently ongoing.
- everolimus / Generic mfg.
[VIRTUAL] Copy number alterations in plasma cell-free DNA from metastatic gastroenteropancreatic neuroendocrine neoplasms. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_298;
CNAs can be used to quantify the tumor fraction in cfDNA over time, which will be linked to tumor progression in our ongoing study, particularly in the promising subgroup of PNEN patients. Kom op tegen Kanker (Stand up to Cancer, the Flemish cancer society), Other Government Agency.
- everolimus / Generic mfg.
[VIRTUAL] The role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_297;
Previous systemic treatments included somatostatin analogs (SSA) 40 pts (100%), everolimus 26 pts (65%) and sunitnib 11 pts (27.5%), others 7 pts (17.5%)... We have identified that baseline NLR and dNRL are significant predictive factors in patients with GEP-NETs treated with PRRT.
- everolimus / Generic mfg.
[VIRTUAL] Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_291;
The setting of rising costs after treatment change from SSA indicates treatment costs as the key driver, rather than NET disease severity. Future studies should investigate the clinical effectiveness of switching from SSA relative to the economic burden imposed by treatment change.
- everolimus / Generic mfg.
[VIRTUAL] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_290;
Furthermore, we have identified some predictive factors to OS that should be taken into consideration. None.
- Keytruda (pembrolizumab) / Merck (MSD), Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_247;
P2
Several case studies evaluating N-based combo with checkpoint inhibitors administered under compassionate use demonstrated that NP led to 1 PR, and the triplet of NPE to prolonged SD. These are case-limited observations but are critical and worth evaluating further in upcoming clinical trials given the continued lack of a standard of care therapy for pts with FLC.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date, Metastases: Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 8, 2020
P1, N=38, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
These are case-limited observations but are critical and worth evaluating further in upcoming clinical trials given the continued lack of a standard of care therapy for pts with FLC. Trial completion date: Jan 2021 --> Apr 2021 | Trial primary completion date: Jan 2021 --> Apr 2021
- |||||| Zolinza (vorinostat) / Merck (MSD)
Clinical: Janku etal show that HDAC inhibitor #vorinostat combined with mTOR inhibitors #sirolimus or #everolimus has encouraging activity in pts with #HodgkinLymphoma. @MDAndersonNews @FilipJankuMD @VivekSubbiah @DavidHongMD @AnaingMD GarridoLagunaMD #ASH20 https://t.co/Zo8yalGG6H (Twitter) - Dec 7, 2020
- | everolimus / Generic mfg., sirolimus / Generic mfg., paclitaxel / Generic mfg.
Journal: A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing. (Pubmed Central) - Dec 5, 2020
Interestingly, we found several broad-spectrum antibiotics and antiretroviral agents. This powerful model predicts several drugs that should be studied in depth to find new chemotherapy regimens and to propose new strategies for osteosarcoma treatment.
- || everolimus / Generic mfg.
Clinical, Journal: Fetal cardiac tumors: prenatal diagnosis, management and prognosis in 18 cases (Pubmed Central) - Dec 5, 2020
Everolimus therapy at a dose of 2x0.25 mg twice a week for three months was started in the postnatal period...Rhabdomyoma are usually multiple and associated with TSC. Rhabdomyomas with TSC are larger, but most regress spontaneously or respond well to medical treatment after birth, and have an excellent long-term prognosis.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France () - Dec 3, 2020 - Abstract #EMUC2020EMUC_144;
P=N/A
Pts were mainly treated in first-line with sunitinib (44% vs 61%) or pazopanib (41% vs 31%)...Among pts who discontinued N (n=162), 49% of elderly pts received subsequent therapy compared to 69% in <75 y.o. population: cabozantinib (67% in elderly vs 83%), axitinib (15% vs 10%) and everolimus (11% vs 5%)...Conclusions In this subpopulation of elderly pts of the WITNESS study, effectiveness results were comparable with those observed in both the overall population in WITNESS and in CM 025. Safety results were consistent with the known safety profile of N.
- everolimus / Generic mfg.
[VIRTUAL] Prognostic and predictive value of total tumor burden particularly on pulmonary localization in patients with clear-cell Renal Cell Carcinoma (mRCC) subjected to molecular-targeted therapy () - Dec 3, 2020 - Abstract #EMUC2020EMUC_112;
Total tumour burden and tumour burden in lungs provides additional information in terms of survival, not included in standard prognosis assessment by MSKCC and Heng. Conclusions In the group of patients with disseminated renal cell clear cell carcinoma treated with molecular targeted therapy in first and second line total tumour burden was associated with a decrease in overall survival and response to treatment. Total tumour burden within the lungs was associated with a decrease in overall survival and response to treatment in patients treated in the first line.
- | everolimus / Generic mfg.
Trial completion, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Dec 3, 2020
P3, N=110, Completed, Sponsor: Istituto Oncologico Veneto IRCCS
Conclusions In the group of patients with disseminated renal cell clear cell carcinoma treated with molecular targeted therapy in first and second line total tumour burden was associated with a decrease in overall survival and response to treatment. Total tumour burden within the lungs was associated with a decrease in overall survival and response to treatment in patients treated in the first line. Active, not recruiting --> Completed
- everolimus / Generic mfg.
[VIRTUAL] 117LU-DOTA-TATE AS A THERAPEUTIC WEAPON IN NEUROENDOCRINE TUMORS (NETS): A CASE REPORT () - Dec 2, 2020 - Abstract #ENEA2020ENEA_33;
The patient remained asymptomatic and without signs of disease progression for 4 years, after PRRT, showing how effective this treatment can be, with a very good safety profile and no significant side effects. Thus, PRRnT appears to be the best therapeutic option for progressive GET-nETs under SSA treatment, given the excellent relationship between effectiveness and tolerability.
- everolimus / Generic mfg.
[VIRTUAL] SPLICING DYSREGULATION IN PANCREATIC NEUROENDOCRINE TUMORS: CONTRIBUTION OF CELF4 SPLICING FACTOR TO PANNET AGGRESSIVENESS () - Dec 2, 2020 - Abstract #ENEA2020ENEA_7;
Moreover, CELF4 silencing altered key signaling pathways and hampered the response of both cell lines to everolimus treatment, thus that CELF4 may play a role in tumor cell aggressiveness and that it could be a suitable actionable tool in PannETs...Our results demonstrate that the splicing factor CELF4 is severely dysregulated in PannETs, where it could influence tumor development and aggressiveness. These findings provide original evidence inviting to further explore this splicing factor as novel a potential diagnostic marker and treatment target in PannETs.
- everolimus / Generic mfg.
[VIRTUAL] Multifocal Hemorrhagic Tumors in a Young Adult () - Dec 2, 2020 - Abstract #ASDP2020ASDP_422;
The patient underwent amputation of the left fifth toe, wide local excision of the heel lesion, and was started on systemic everolimus...PMH is a rare vascular tumor that can mimic other spindled and epithelioid entities. This case demonstrates a dramatic clinical presentation of PMH with metastases and highlights PMH as a cause of multifocal hemorrhagic tumors in young adults.
- || Xofigo (radium Ra-223 dichloride) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 2, 2020
P2, N=283, Active, not recruiting, Sponsor: Bayer
This case demonstrates a dramatic clinical presentation of PMH with metastases and highlights PMH as a cause of multifocal hemorrhagic tumors in young adults. Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021
- || metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Dec 2, 2020
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021 Trial completion date: Oct 2020 --> Oct 2023 | Trial primary completion date: Oct 2020 --> Oct 2022
- | everolimus / Generic mfg.
Journal: Predicting Radiation Resistance in Breast Cancer with Expression Status of Phosphorylated S6K1. (Pubmed Central) - Dec 1, 2020
Furthermore, the combination of radiation with treatment of everolimus, an mTOR-S6K1 pathway inhibitor, sensitised CD44/CD24 MCF7 cells to a greater extent than MCF7 cells. This study provides in vivo and in vitro evidence for p-S6K1 expression status as an important marker for predicting the resistance to radiotherapy and as a possible target for radio-sensitization in breast cancer patients.
- | everolimus / Generic mfg., gefitinib / Generic mfg.
Journal: Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. (Pubmed Central) - Dec 1, 2020
Gene and protein expression analysis revealed significant downregulation of cell cycle regulators after exposure to combined treatment. Collectively, these results suggested that dual inhibition of mTOR and EGFR may be an effective treatment for TNBC with activating mutations of PI3K.
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial completion date, Post-transplantation: OCTET-Ever: Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (clinicaltrials.gov) - Dec 1, 2020
P2, N=19, Active, not recruiting, Sponsor: University of Cologne
Collectively, these results suggested that dual inhibition of mTOR and EGFR may be an effective treatment for TNBC with activating mutations of PI3K. Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2020
- || everolimus / Generic mfg.
Trial completion date, Trial primary completion date: CLEVER-ACS: Controlled Level EVERolimus in Acute Coronary Syndromes (clinicaltrials.gov) - Nov 30, 2020
P1/2, N=150, Recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2020 Trial completion date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Sep 2021
- | everolimus / Generic mfg., sirolimus / Generic mfg.
Preclinical, Journal: Inhibitor for protein disulfide-isomerase family A member 3 enhances the antiproliferative effect of inhibitor for mechanistic target of rapamycin in liver cancer: An in vitro study on combination treatment with everolimus and 16F16. (Pubmed Central) - Nov 28, 2020
The inhibition was associated with reduction of 4E-BP1 phosphorylation, which formed a complex with PDIA3. Combination treatment with Ev and 16F16 could be a novel therapeutic strategy for liver cancer.
- everolimus / Generic mfg.
[VIRTUAL] Early postnatal mTOR inhibitor treatment in a mouse model of TSC with epilepsy delays onset of hyperexcitability, epilepsy, and mortality () - Nov 28, 2020 - Abstract #AES2020AES_1079;
Examination of aberrant circuit behavior may help reveal mechanisms of drug resistance and seizure recurrence. Funding: Ruth L. Kirschstein NRSA Training Grant for Multidisciplinary Training in Brain Disorders and Development
- everolimus / Generic mfg., sirolimus / Generic mfg.
[VIRTUAL] Efficacy and safety of rapamycin in children with drug-resistant epilepsy associated with tuberous sclerosis complex () - Nov 28, 2020 - Abstract #AES2020AES_470;
Long-term use of rapamycin, especially in combination with vigabatrin, might be a beneficial therapeutic option in the treatment of drug-resistant epilepsy in children with TSC. Funding: The work was partially supported by the grant EPIMARKER of the Polish National Center for Research and Development No STRATEGMED3/306306/4/2016.
- everolimus / Generic mfg.
[VIRTUAL] Everolimus as a precision medicine for epilepsy due to pathogenic variants in DEPDC5 () - Nov 28, 2020 - Abstract #AES2020AES_298;
Both cases had previously failed more than six anti-seizure medicines and following initiation of everolimus experienced a significant improvement in seizure control due to an adoption of a precision medicine approach. Funding: This work was supported by research grants from Epilepsy Ireland, the Health Research Board (MRCG-HRB-2018-05) and Science Foundation Ireland (SFI) (16/RC/3948 and 13/CDA/2223) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners
- || everolimus / Generic mfg.
And, acknowledge that mTor inhib, like everolimus, also have anti-angiogenic properties. (Twitter) - Nov 27, 2020
- || imlunestrant (LY3484356) / Eli Lilly
Trial primary completion date, Combination therapy, Monotherapy, Metastases: EMBER: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (clinicaltrials.gov) - Nov 25, 2020
P1a/1b, N=460, Recruiting, Sponsor: Eli Lilly and Company
Funding: This work was supported by research grants from Epilepsy Ireland, the Health Research Board (MRCG-HRB-2018-05) and Science Foundation Ireland (SFI) (16/RC/3948 and 13/CDA/2223) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners Trial primary completion date: Oct 2020 --> Feb 2021
- | xentuzumab (BI-836845) / Boehringer Ingelheim
Trial completion date, Combination therapy, Metastases: BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 24, 2020
P1, N=164, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2020 --> Feb 2021 Trial completion date: Nov 2020 --> Jul 2021
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Nov 23, 2020
P2, N=343, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Nov 2020 --> Jul 2021 Trial completion date: Nov 2020 --> Jul 2021
- || doxycycline / Generic mfg., Pierre Fabre, everolimus / Generic mfg., sirolimus / Generic mfg.
Clinical, Journal: The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. (Pubmed Central) - Nov 22, 2020
Doxycycline and triptorelin were not recommended for the treatment of LAM because no beneficial outcomes were consistently observed. The efficacy and safety of combination therapy remain to be further explored.
- | rapamycin topical (PTX-022) / Palvella Therapeutics, Ligand
Journal: Structural insights into CYP107G1 from rapamycin-producing Streptomyces rapamycinicus. (Pubmed Central) - Nov 21, 2020
Hence, CYP107G1 has a relatively rigid structure with versatile loops to accommodate a bulky substrate. The everolimus molecule is bound to the substrate-binding pocket in the shape of a squeezed donut, and its elongated structure is bound perpendicular to a planar heme plane and I-helix.
- ||| everolimus / Generic mfg.
Tell that to every renal cell carcinoma trial designer who made the comparator arm everolimus (Twitter) - Nov 21, 2020
- | Sutent (sunitinib) / Pfizer
Trial termination, Metastases: TSAP: Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (clinicaltrials.gov) - Nov 20, 2020
P=N/A, N=45, Terminated, Sponsor: VU University Medical Center
The everolimus molecule is bound to the substrate-binding pocket in the shape of a squeezed donut, and its elongated structure is bound perpendicular to a planar heme plane and I-helix. Active, not recruiting --> Terminated
- | Votrient (pazopanib) / Novartis, sunitinib / Generic mfg., Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Metastases: ICK: Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (clinicaltrials.gov) - Nov 20, 2020
P=N/A, N=43, Active, not recruiting, Sponsor: VU University Medical Center
Active, not recruiting --> Terminated Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Lenvatinib Plus Everolimus Induces Responses in Rare RCC Population https://t.co/qBY8goCZbA via @targetedonc (Twitter) - Nov 19, 2020
- ||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Nicely done @TargetedOnc Q&A with @DrTHut on lenvatinib + everolimus. Powerful combination. Good treatment option for patients. @kidneycan (Twitter) - Nov 19, 2020
- everolimus / Generic mfg.
Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5-7 Years: From The DISAPEAR Trial And A Meta-Analysis Of The Absorb Stent From Abbott (Bonnet Creek Ballroom - Salons VII, VIII, X and XI (7, 8, 10 and 11)) - Nov 19, 2020 - Abstract #VEITH2021VEITH_1031;
- everolimus / Generic mfg.
10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations (Bonnet Creek Ballroom - Salons VII, VIII, X and XI (7, 8, 10 and 11)) - Nov 19, 2020 - Abstract #VEITH2021VEITH_314;
- everolimus / Generic mfg.
[VIRTUAL] Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5-7 Years: From The DISAPEAR Trial And A Meta-Analysis Of The Absorb Stent From Abbott (Grand Ballroom East, 3rd Floor) - Nov 19, 2020 - Abstract #VEITH2020VEITH_1031;
- everolimus / Generic mfg.
[VIRTUAL] 10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations (Grand Ballroom East, 3rd Floor) - Nov 19, 2020 - Abstract #VEITH2020VEITH_314;
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, HEOR: Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes. (Pubmed Central) - Nov 19, 2020
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 The evidence from this study and previous work highlights the importance of the assumptions underlying any model structure, and the need to validate assumptions regarding survival and the application of treatment effects against what is known about the characteristics of the disease.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 19, 2020
P3, N=959, Active, not recruiting, Sponsor: Eisai Inc.
The evidence from this study and previous work highlights the importance of the assumptions underlying any model structure, and the need to validate assumptions regarding survival and the application of treatment effects against what is known about the characteristics of the disease. Trial completion date: Apr 2022 --> Apr 2021
- | everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: Direct regulation of fibroblast growth factor 23 by energy intake through mTOR. (Pubmed Central) - Nov 19, 2020
Cells incubated with HG and mechanistic target of rapamycin (mTOR) inhibitors expressed low mRNA FGF23, similar to the values obtained in LG. In conclusion, this study shows a direct regulation of FGF23 production by energy availability and demonstrates that the mTOR signaling pathway plays a central role in this regulatory system.
- | Trial completion date, Trial primary completion date: Efficacy and Safety of Precision Therapy in Refractory Tumor (clinicaltrials.gov) - Nov 18, 2020
P2, N=300, Recruiting, Sponsor: Baodong Qin
In conclusion, this study shows a direct regulation of FGF23 production by energy availability and demonstrates that the mTOR signaling pathway plays a central role in this regulatory system. Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Jun 2023
- | everolimus / Generic mfg.
Biomarker, Journal: Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus. (Pubmed Central) - Nov 18, 2020
Interestingly, QGP-1 spheroid cells, which exhibited cancer stem cell-like features, exhibited lower expression of Prdx2 and mTOR. The results suggest that Prdx2 expression level and its activity may be a potential predictive biomarker for therapeutic response or resistance to everolimus in pNEN.
- || everolimus / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. (Pubmed Central) - Nov 18, 2020
We found two precocious ∆SUV% thresholds capable of identifying HR+ HER2-mBC patients, which would achieve long-term benefit or long-term survival during everolimus-exemestane therapy. These results warrant further validation in prospective studies and should be integrated with molecular biomarkers related to tumor metabolism and mTORC1 signaling.
- | everolimus / Generic mfg.
Journal, HEOR: Cost-effectiveness of lutetium (Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. (Pubmed Central) - Nov 18, 2020
These results warrant further validation in prospective studies and should be integrated with molecular biomarkers related to tumor metabolism and mTORC1 signaling. In both Sweden and Norway, from a healthcare provider perspective, Lu-Dotatate is likely to be considered cost-effective relative to everolimus for the treatment of patients with unresectable or metastatic, progressive midgut-NETs or P-NETs.
- |||||||||| Obnitix (MSC-FFM) / Medac
New P3 trial, Stroma: IDUNN: Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (clinicaltrials.gov) - Nov 15, 2020
P3, N=210, Not yet recruiting, Sponsor: medac GmbH
- | everolimus / Generic mfg.
Biomarker, Journal: Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy. (Pubmed Central) - Nov 14, 2020
Overall, in this study, the mutation rate of TSC-AML patients is much lower than other reports. Short-term everolimus treatment for TSC-AML is effective and safe, but the stability is much lower than long-term therapy.